Quantcast

Latest Élan Stories

2006-03-08 10:49:50

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday. The committee voted 7-5 in favor of Tysabri as an initial treatment for some patients. The panel was due to vote later Wednesday on whether to recommend resumed sales for the drug, which was pulled from the market in February 2005 after three patients developed a...

2006-03-01 21:15:39

By Karla Gale NEW YORK (Reuters Health) - Tysabri, a drug made by Biogen Idec and Elan Pharmaceuticals, significantly reduces the rate of disease progression in patients with relapsing multiple sclerosis (MS), according to the results of two trials reported in this week's New England Journal of Medicine. "The available drugs for MS, interferon and Copaxone, have been shown in trials to reduce relapse rate by one third," Dr. Richard A. Rudick, of the Cleveland Clinic Foundation in...

2004-11-27 12:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc. and Irish drug maker Elan Corp. -- is known chemically as natalizumab. During clinical trials, it was called Antegren, but in the Food and Drug Administration announcement, the name was changed to Tysabri....

2004-11-26 18:00:09

FRIDAY, Nov. 26 (HealthDayNews) -- The U.S. Food and Drug Administration has approved Tysabri (natalizumab) as a new treatment for multiple sclerosis. The incurable nervous system disease affects about 350,000 Americans. The drug, known as a humanized monoclonal antibody, appears to work by preventing immune cells from migrating from the bloodstream to the brain, where they cause inflammation and lead to nerve fiber damage, its two manufacturers said in a statement. The medication is...

2004-11-26 06:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc. and Irish drug maker Elan Corp. -- is known chemically as natalizumab. During clinical trials, it was called Antegren, but in the Food and Drug Administration announcement, the name was changed to Tysabri....


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related